{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:38:05Z","timestamp":1786995485160,"version":"build-2736575974"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","progcardvascdis.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.pcad.2016.10.005","type":"journal-article","created":{"date-parts":[[2016,10,28]],"date-time":"2016-10-28T01:17:29Z","timestamp":1477617449000},"page":"247-252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Beta-Adrenergic Receptor Blockers in Hypertension: Alive and Well"],"prefix":"10.1016","volume":"59","author":[{"given":"William H.","family":"Frishman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2016.10.005_bb0005","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1136\/bmj.1.5392.1227","article-title":"Hypotensive action of pronethalol","volume":"1","author":"Prichard","year":"1964","journal-title":"Br Med J"},{"key":"10.1016\/j.pcad.2016.10.005_bb0010","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/bmj.2.5411.725","article-title":"Use of propranolol (Inderal) in the treatment of hypertension","volume":"2","author":"Prichard","year":"1964","journal-title":"Br Med J"},{"key":"10.1016\/j.pcad.2016.10.005_bb0015","series-title":"Cardiovascular Pharmacotherapeutics","first-page":"57","article-title":"Alpha- and beta-adrenergic blocking drugs","author":"Frishman","year":"2011"},{"key":"10.1016\/j.pcad.2016.10.005_bb0020","series-title":"Hypertension Primer","first-page":"446","article-title":"\u03b2-Adrenergic blockers","author":"Frishman","year":"2008"},{"key":"10.1016\/j.pcad.2016.10.005_bb0025","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/00132580-200211000-00005","article-title":"Comprehensive management of hypertensive emergencies and urgencies","volume":"4","author":"Mansoor","year":"2002","journal-title":"Heart Dis"},{"key":"10.1016\/j.pcad.2016.10.005_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmj.b1665","article-title":"Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiologic studies","volume":"338","author":"Law","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.pcad.2016.10.005_bb0035","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","article-title":"2013 ESH\/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"34","author":"Mancia","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2016.10.005_bb0040","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1001\/jama.279.23.1903","article-title":"Are beta blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review","volume":"279","author":"Messerli","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2016.10.005_bb0045","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.jacc.2008.08.008","article-title":"Beta blockers in hypertension. Adding insult to injury (editorial comment)","volume":"52","author":"Kaplan","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2016.10.005_bb0050","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.304.6824.405","volume":"304","year":"1992","journal-title":"Br Med J"},{"key":"10.1016\/j.pcad.2016.10.005_bb0055","doi-asserted-by":"crossref","first-page":"941","DOI":"10.3109\/10641969309037083","article-title":"MRC trial of treatment in elderly hypertensives","volume":"15","author":"Lever","year":"1993","journal-title":"Clin Exp Hypertens"},{"key":"10.1016\/j.pcad.2016.10.005_bb0060","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"Dahlof","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2016.10.005_bb0065","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.jacc.2011.01.008","volume":"57","author":"Aronow","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2016.10.005_bb0070","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(05)67573-3","article-title":"Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis","volume":"366","author":"Lindholm","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2016.10.005_bb0075","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1503\/cmaj.060110","article-title":"Reexamining the efficacy of beta blockers for the treatment of hypertension: a meta analysis","volume":"174","author":"Khan","year":"2006","journal-title":"CMAJ"},{"key":"10.1016\/j.pcad.2016.10.005_bb0080","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1161\/CIRCULATIONAHA.105.595496","article-title":"Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAF\u00c9) study","volume":"113","author":"Williams","year":"2006","journal-title":"Circulation"},{"issue":"9 Suppl.","key":"10.1016\/j.pcad.2016.10.005_bb0085","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1524-6175.2007.06633.x","article-title":"A historical perspective on the development of \u03b2-adrenergic blockers","volume":"3","author":"Frishman","year":"2007","journal-title":"J Clin Hypertens"},{"key":"10.1016\/j.pcad.2016.10.005_bb0090","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.amjmed.2008.06.025","article-title":"Fifty years of beta-adrenergic blockade: a golden era in clinical medicine and molecular pharmacology (commentary)","volume":"121","author":"Frishman","year":"2008","journal-title":"Am J Med"},{"key":"10.1016\/j.pcad.2016.10.005_bb0095","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/j.jacc.2015.02.038","article-title":"Treatment of hypertension in patients with coronary artery disease","volume":"65","author":"Rosendorff","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2016.10.005_bb0100","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.amjmed.2015.10.045","article-title":"Threatment of hypertension in patients with coronary artery disease. A case-based summary of the 2014 AHA\/ACC\/ASH scientific statement","volume":"129","author":"Rosendorff","year":"2015","journal-title":"Am J Med"},{"key":"10.1016\/j.pcad.2016.10.005_bb0105","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/j.1524-6175.2007.07548.x","article-title":"The efficacy and tolerability of nebivolol in hypertensive African American patients","volume":"9","author":"Saunders","year":"2007","journal-title":"J Clin Hypertens"},{"key":"10.1016\/j.pcad.2016.10.005_bb0110","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/01.crd.0000137738.16166.cc","article-title":"Pathophysiology and medical management of systemic hypertension in pregnancy","volume":"13","author":"Frishman","year":"2015","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.pcad.2016.10.005_bb0115","first-page":"565","article-title":"\u03b2-Adrenergic blockers: a 50-year historical perspective","volume":"15","author":"Frishman","year":"2008","journal-title":"Am J Ther"},{"key":"10.1016\/j.pcad.2016.10.005_bb0120","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1056\/NEJM198304213081606","article-title":"Pindolol: a new beta-adrenoceptor antagonist with partial agonist activity","volume":"308","author":"Frishman","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2016.10.005_bb0125","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJM199812103392407","article-title":"Carvedilol","volume":"339","author":"Frishman","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2016.10.005_bb0130","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/01.crd.0000223651.03023.8e","article-title":"Nebivolol, a new therapy update","volume":"14","author":"Sule","year":"2006","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.pcad.2016.10.005_bb0135","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJM198403293101306","article-title":"Beta-adrenergic blockade for survivors of acute myocardial infarction","volume":"310","author":"Frishman","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2016.10.005_bb0140","series-title":"Hypertension: A Companion to Braunwald's Heart Disease","first-page":"172","article-title":"\u03b2-Blockers in hypertension","author":"Carlberg","year":"2012"},{"key":"10.1016\/j.pcad.2016.10.005_bb0145","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0002-9343(03)00158-X","article-title":"A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension","volume":"115","author":"Klingbeil","year":"2003","journal-title":"Am J Med"},{"key":"10.1016\/j.pcad.2016.10.005_bb0150","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/S0140-6736(10)60960-9","article-title":"Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial","volume":"376","author":"Ong","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2016.10.005_bb0155","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3949\/ccjm.75.7.513","article-title":"Perioperative beta-blockers in noncardiac surgery: evolution of the evidence","volume":"75","author":"Harte","year":"2008","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.pcad.2016.10.005_bb0160","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJM199612053352301","article-title":"Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter study of perioperative ischemia research group","volume":"335","author":"Mangano","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2016.10.005_bb0165","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJM199912093412402","article-title":"The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group","volume":"341","author":"Poldermans","year":"1999","journal-title":"N Engl J Med"},{"issue":"43","key":"10.1016\/j.pcad.2016.10.005_bb0170","first-page":"1","article-title":"Making health care safer: a critical analysis of patient safety practices","volume":"i-x","author":"Shojania","year":"2003","journal-title":"Evid Rep Technol Assess (Summ)"},{"key":"10.1016\/j.pcad.2016.10.005_bb0175","series-title":"National Quality Forum: Safe practices for better healthcare \u2013 2006 update","year":"2006"},{"key":"10.1016\/j.pcad.2016.10.005_bb0180","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1016\/j.jacc.2009.07.004","article-title":"2009 ACCF\/AHA focused update on perioperative beta blockade","volume":"54","author":"Fleischmann","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2016.10.005_bb0185","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/S0140-6736(08)60601-7","article-title":"Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE Trial): a randomized controlled trial","volume":"371","author":"POISE Study Group","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2016.10.005_bb0190","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(08)61560-3","article-title":"Perioperative beta blockers in patients having non-cardiac surgery: a meta-analysis","volume":"6","author":"Bangalore","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2016.10.005_bb0195","first-page":"1","article-title":"\u03b2-Blocker use and mortality in COPD patients after myocardial infarction: a Swedish nationwide observational study","volume":"4","author":"Andell","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.pcad.2016.10.005_bb0200","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.amjcard.2007.05.057","article-title":"A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus","volume":"100","author":"Bangalore","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2016.10.005_bb0205","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1161\/CIRCULATIONAHA.108.828897","article-title":"Antihypertensive efficacy of aliskiren: is hydrochlorothiazide an appropriate benchmark?","volume":"119","author":"Messerli","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2016.10.005_bb0210","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1056\/NEJMcp1502240","article-title":"Chronic stable angina","volume":"374","author":"Ohman","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2016.10.005_bb0215","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1001\/jama.292.18.2227","article-title":"For the GEMINI investigators: metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial","volume":"292","author":"Bakris","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2016.10.005_bb0220","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.amjmed.2006.10.017","article-title":"GEMINI investigators. Body weight changes with beta-blocker use: results from GEMINI","volume":"120","author":"Messerli","year":"2007","journal-title":"Am J Med"},{"key":"10.1016\/j.pcad.2016.10.005_bb0225","series-title":"Cardiovascular Pharmacotherapeutics","first-page":"493","article-title":"Cardiovascular drug interactions","author":"Cheng-Lai","year":"2011"},{"key":"10.1016\/j.pcad.2016.10.005_bb0230","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults. Report from the panel members appointed to the eighth joint National Committee (JNC)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2016.10.005_bb0235","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowing for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2016.10.005_bb0240","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.jacc.2008.06.048","article-title":"Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension","volume":"52","author":"Bangalore","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2016.10.005_bb0245","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1001\/jama.2016.7070","article-title":"SPRINT results in older patients: how low to go?","volume":"315","author":"Chobanian","year":"2016","journal-title":"JAMA"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062016301220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062016301220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T01:51:40Z","timestamp":1536285100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062016301220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S0033062016301220"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2016.10.005","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beta-Adrenergic Receptor Blockers in Hypertension: Alive and Well","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2016.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}